2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
[HTML][HTML] Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
[HTML][HTML] Heart failure with mid-range or mildly reduced ejection fraction
G Savarese, D Stolfo, G Sinagra, LH Lund - Nature Reviews Cardiology, 2022 - nature.com
Left ventricular ejection fraction (EF) remains the major parameter for diagnosis,
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …
phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure …
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
SD Solomon, RA de Boer, D DeMets… - European journal of …, 2021 - Wiley Online Library
Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
Aims No therapy has shown to reduce the risk of hospitalization for heart failure across the
entire range of ejection fractions seen in clinical practice. We assessed the influence of …
entire range of ejection fractions seen in clinical practice. We assessed the influence of …
Heart failure with preserved ejection fraction: a review
MM Redfield, BA Borlaug - Jama, 2023 - jamanetwork.com
Importance Heart failure with preserved ejection fraction (HFpEF), defined as HF with an EF
of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 …
of 50% or higher at diagnosis, affects approximately 3 million people in the US and up to 32 …